Free Trial

Pharvaris (NASDAQ:PHVS) Releases Quarterly Earnings Results

Pharvaris logo with Medical background
Remove Ads

Pharvaris (NASDAQ:PHVS - Get Free Report) released its quarterly earnings results on Monday. The company reported ($0.68) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.74) by $0.06, Zacks reports.

Pharvaris Trading Up 0.8 %

Shares of PHVS traded up $0.10 during trading hours on Friday, reaching $12.00. The company had a trading volume of 56,660 shares, compared to its average volume of 71,419. Pharvaris has a 12-month low of $11.51 and a 12-month high of $25.50. The firm has a 50 day simple moving average of $15.55 and a 200-day simple moving average of $18.36. The company has a market capitalization of $627.48 million, a price-to-earnings ratio of -4.29 and a beta of -2.84.

Analyst Ratings Changes

Separately, JMP Securities upped their price target on shares of Pharvaris from $46.00 to $55.00 and gave the company a "market outperform" rating in a research report on Friday, January 31st.

Check Out Our Latest Report on PHVS

About Pharvaris

(Get Free Report)

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.

Featured Articles

Earnings History for Pharvaris (NASDAQ:PHVS)

Should You Invest $1,000 in Pharvaris Right Now?

Before you consider Pharvaris, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pharvaris wasn't on the list.

While Pharvaris currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report
Like this article? Share it with a colleague.
Remove Ads

Featured Articles and Offers

Donald Trump Owns These 7 Stocks, Should You?

Donald Trump Owns These 7 Stocks, Should You?

He’s one of the most talked-about billionaires in the world—but when it comes to investing, Donald Trump’s stock picks are shockingly… low-key.

Related Videos

Donald Trump Owns These 7 Stocks, Should You?
Quantum Stocks Are Heating Up Again — 7 to Watch Now
Quantum Stocks Are Heating Up Again — 7 to Watch Now

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines

Remove Ads